Erythropoietin as a possible neuroprotective agent in patients with schizophrenia

Abstract

Event Abstract Back to Event Erythropoietin as a possible neuroprotective agent in patients with schizophrenia Diana Maria Henao-Parra1, Janneth Gonzalez1 and George E. Barreto1* 1 Pontificia Universidad Javeriana, Colombia It is estimated that about 1% of the world population has Schizophrenia. Recently, even without consensus among researchers, Schizophrenia has been defined as a progressive neurodevelopmental disorder, a disease with variable progression and altered brain development. Similarly to other neurodegenerative disorders, Schizophrenia is characterized by increased cell apoptosis, glutamate excitotoxicity and oxidative stress processes. Potential protective molecules shall include neurosteroids, and antipsychotic agents that have been successfully used in diseases with similar characteristics such as Alzheimer´s Disease or Parkinson´s Syndrome. For example, erythropoietin (EPO), a hematopoietic growth factor synthesized in the liver and in the brain by astrocytes and neurons has been extensively studied as a promising neuroprotective agent. At the cellular level, it is known that EPO binds to its specific receptor, EPOR, activating a signaling cascade associated with anti-apoptotic factors such as bcl-2 and augmented expression of superoxide dismutase, in which these molecules might be trigger protective responses in the brain. In this context, understanding the mechanisms of action at the cellular and molecular level and the effects of this molecule in patients with neurodegenerative diseases will allow to establish future perspectives on the use of this cytokinin as a neuroprotective agent in patients with Schizophrenia. Figure 1 Keywords: Schizophrenia, Erythropoietin, Astrocytes, Neurons, Neuroprotection Conference: Latin-American School on glial cells in the diseased brain (IBRO), Bogotá, Colombia, 13 Jul - 17 Jul, 2015. Presentation Type: Poster Presentation Topic: Neurodevelopment Citation: Henao-Parra D, Gonzalez J and Barreto G (2015). Erythropoietin as a possible neuroprotective agent in patients with schizophrenia. Conference Abstract: Latin-American School on glial cells in the diseased brain (IBRO). doi: 10.3389/conf.fncel.2015.35.00026 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 23 Feb 2015; Published Online: 11 Jun 2015. * Correspondence: Prof. George E. Barreto, Pontificia Universidad Javeriana, Bogotá, Colombia, gesbarreto@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Diana Maria Henao-Parra Janneth Gonzalez George E. Barreto Google Diana Maria Henao-Parra Janneth Gonzalez George E. Barreto Google Scholar Diana Maria Henao-Parra Janneth Gonzalez George E. Barreto PubMed Diana Maria Henao-Parra Janneth Gonzalez George E. Barreto Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.